James Edgemond Sells 7,792 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHR) CFO James Edgemond sold 7,792 shares of United Therapeutics stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $358.62, for a total value of $2,794,367.04. Following the sale, the chief financial officer now directly owns 4,802 shares of the company’s stock, valued at $1,722,093.24. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

James Edgemond also recently made the following trade(s):

• On Monday, September 23rd, James Edgemond sold 7,796 shares of United Therapeutics stock. The stock was sold at an average price of $354.04, for a total value of $2,760,095.84.
• On Monday, September 9th, James Edgemond sold 7,802 shares of United Therapeutics stock. The shares were sold at an average price of $345.41, for a total value of $2,694,888.82.
• On Tuesday, September 3rd, James Edgemond sold 7,785 shares of United Therapeutics stock. The stock was sold at an average price of $362.37, for a total transaction of $2,821,050.45.

United Therapeutics Price Performance

United Therapeutics stock opened at $357.83 on Wednesday. The business has a 50 day simple moving average of $343.01 and a 200-day simple moving average of $297.78. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $366.08. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.35 and a quick ratio of 4.18. The stock has a market capitalization of $15.87 billion, a PE ratio of 16.92, a price-to-earnings-growth ratio of 1.30 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 EPS for the quarter, missing the consensus estimate of $6.33 by ($0.48). United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The firm had revenue of $714.90 million during the quarter, compared to analyst estimates of $691.87 million. During the same quarter last year, the business posted $5.24 EPS. The firm’s revenue was up 19.8% on a year-over-year basis. Equities analysts predict that United Therapeutics Co. will post 24.71 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. UBS Group lifted their price target on shares of United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a research note on Monday, July 8th. StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 2nd. HC Wainwright reissued a “buy” rating and issued a $400.00 target price on shares of United Therapeutics in a research report on Thursday, August 1st. Oppenheimer lifted their price target on United Therapeutics from $400.00 to $575.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 28th. Finally, Jefferies Financial Group boosted their price objective on United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a research note on Monday, September 23rd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $357.17.

Hedge Funds Weigh In On United Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. ClariVest Asset Management LLC lifted its holdings in shares of United Therapeutics by 120.0% in the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 42 shares during the period. V Square Quantitative Management LLC acquired a new stake in United Therapeutics in the second quarter valued at $30,000. Rise Advisors LLC purchased a new stake in shares of United Therapeutics during the 1st quarter worth $32,000. Innealta Capital LLC acquired a new position in shares of United Therapeutics during the 2nd quarter worth $33,000. Finally, Benjamin F. Edwards & Company Inc. increased its holdings in shares of United Therapeutics by 63.6% in the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock valued at $69,000 after purchasing an additional 117 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.